Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$3.17 USD
+0.01 (0.32%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $3.16 -0.01 (-0.32%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Brokerage Reports
Fate Therapeutics, Inc. [FATE]
Reports for Purchase
Showing records 141 - 160 ( 439 total )
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q21: Durability Data From FT516 in BCell Lymphoma Coming up on Aug 19th
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Investor Event Later This Month; 2Q21 Financials; Modulating PT to $121
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Invitation: ROTH Virtual Healthcare Private Company Forum on June 28, 2021
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are hosting a Virtual Healthcare Private Company Forum on June 28, 2021
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Updated FT516 + Rituxan Data Look Favorable; Upgrading to Buy and $120 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NK Therapy Shows Dose Response but Duration Remains Unknown
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASCO 2021 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D